

PTO/SU/08D (08-03)

Substantive for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b> (use as many sheets as necessary)				<b>Complete if Known</b>	
				Application Number	09/724,570
				Filing Date	November 28, 2000
				First Named Inventor	Schenk, Dale B.
				Art Unit	1647
				Examiner Name	Nichols, Christopher J.
Sheet	1	of	1	Attorney Docket Number	015270-005914US


NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T 2
	551	HSIAO et al., "From prion diseases to Alzheimer's disease," J. Neural. Transm., (suppl.) 49:135-144 (1997).	

Examiner Signature		Date Considered	10/28/04
-----------------------	--	--------------------	----------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. (Include copy of this form with next communication to applicant.)

<sup>1</sup> Applicant's unique citation designation number (optional). \* Applicant is to place a check mark here if English language Translation is attached.

60341445 v1



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.  
Supplemental form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 1 of 24

### Complete If Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

### U.S. PATENT DOCUMENTS

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
↓	360	2003/0073655 A1	04-17-2003	Chain	_____
	370	2003/0068325 A1	04-10-2003	Wang	_____
	378	2002/0197258 A1	12-26-2003	Ghanbari et al.	_____
	366	2002/0187157 A1	12-12-2002	Jensen et al.	_____
	377	2002/0168377 A1	11-14-2002	Schaetzl	_____
	340	2002/0162129 A1	10-31-2002	Lannfelt	_____
	395	2002/0160394 A1	10-31-2002	Wu	_____
	326	2002/0136718 A1	09-26-2002	Raso	_____
	379	2002/0132268 A1	09-19-2002	Chang et al.	_____
	365	2002/0133001 A1	09-19-2002	Gefter et al.	_____
	325	2001/0102261 A1	08-01-2002	Raso	_____
	362	2002/0094335 A1	07-18-2002	Chalifour et al.	_____
	306	6,417,178 B1	07-09-2002	Klunk et al.	_____
	376	2002/0086847 A1	07-04-2002	Chain	_____
	405	6,399,314 B1	06-04-2002	Krishnamurthy	_____
	342	2002/0009445 A1	01-24-2002	Du et al.	_____
	267	6,294,171 B2	09-25-2001	McMichael	_____
	381	2001/0021769 A1	09-13-2001	Prusiner	_____
	401	6,284,533 B1	09-04-2001	Thomas	_____
	234	6,284,221 B1	09-04-2001	Schenk, et al.	_____
	300	2001/0018053 A1	08-30-2001	McMichael	_____
	230	6,262,335 B1	07-17-2001	Hsiao et al.	_____
	345	2002/0077288 A1	06-21-2001	Frangione	_____
	196	6,150,091	11-21-2000	Pandolfo et al.	_____
	231	6,114,133	09-05-2000	Seubert et al.	_____
	1	6,057,367	05-02-2000	Stamler et al.	_____
	221	5,989,566	11-23-1999	Cobb et al.	_____
	2	5,958,883	09-28-1999	Snow	_____
	3	5,955,317	09-21-1999	Suzuki et al.	_____
	4	5,955,079	09-21-1999	Mond et al.	_____
↓	346	5,935,927	08-10-1999	Vitek et al.	_____
↓	5	5,877,399	03-02-1999	Hsiao et al.	_____

Examiner  
Signature

*g. nichols*


Date  
Considered

3/25/04

<sup>1</sup> EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>2</sup> Applicant's unique citation designation number (optional). <sup>3</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>4</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>5</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>6</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>7</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60106599 v1



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 2 of 24

### Complete If Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

CN	6	5,869,093	02-09-1999	Weiner et al.	
	7	5,869,054	02-09-1999	Weiner et al.	
	8	5,854,204	12-29-1998	Findeis et al.	
	9	5,851,996	12-22-1998	Kline	
	10	5,849,298	12-15-1998	Weiner et al.	
	382	5,846,533	12-08-1998	Prusiner	
	321	5,837,672	11-17-1998	Schenk et al.	
	11	5,837,473	11-17-1998	Maggio et al.	
	353	5,824,322	10-20-1998	Balasubramanian	
	12	5,786,180	07-28-1998	Konig et al.	
	207	5,780,587	07-14-1998	Potter	
	357	5,776,468 B1	07-07-1998	Hauser et al.	
	13	5,753,624	05-19-1998	McMichael et al.	
	380	5,750,361	05-12-1998	Prusiner et al.	
	14	5,750,349	05-12-1998	Suzuki et al.	
	197	5,744,368	04-28-1998	Goldgaber et al.	
	211	5,736,142	04-07-1998	Settle et al.	
	15	5,733,547	03-31-1998	Weiner et al.	
	373	5,721,130	02-24-1998	Seubert et al.	
	16	5,688,651	11-18-1997	Solomon	
	17	5,679,348	10-21-1997	Nesburn et al.	
	18	5,645,820	07-08-1997	Hafler et al.	
	19	5,641,474	06-24-1997	Hafler et al.	
	20	5,641,473	06-24-1997	Hafler et al.	
	356	5,622,701	04-22-1997	Berg	
	21	5,612,486	03-18-1997	McConlogue et al.	
	22	5,605,811	02-25-1997	Seubert et al.	
	320	5,593,846	01-14-1997	Schenk et al.	
	23	5,585,100	12-17-1996	Mond et al.	
	358	5,583,112 B2	12-10-1996	Kensil et al.	
	24	5,571,500	11-05-1996	Hafler et al.	
	25	5,571,499	11-05-1996	Hafler et al.	
Δ	403	5,464,823	11-07-1995	Lehrer et al.	
	175	5,441,870	08-15-1995	Seubert, et al.	
CN	26	5,434,170	07-18-1995	Andrulis, Jr.	

Examiner  
Signature

*C. Nichols*


Date  
Considered

3/25/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60106599 v1



PTO/SB/08A (10-01)

Approved for use through 10/31/2002. OMB 0851-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 3 of 24

Complete if Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

CSO	27	5,387,742	02-07-1995	Cordell	
	181	5,270,165	12-14-1993	Van Nostrand et al.	
	284	5,231,170	07-27-1993	Averback	
	28	5,231,000	07-27-1993	Majocha et al.	
	29	5,220,013	06-15-1993	Ponte et al.	
	30	5,208,036	05-04-1993	Eppstein et al.	
	31	5,192,753	03-09-1993	McGeer et al.	
	32	5,187,153	02-16-1993	Cordell et al.	
	33	5,057,540	10-15-1991	Kensil et al.	
	198	5,004,697	04-20-1991	Pardridge	
CSO	402	4,713,366	12-15-1987	Stevens	
CSO	34	4,666,829	05-19-1987	Glenner et al.	

**U.S. PATENT DOCUMENTS**

Examiner	Cite No. <sup>1</sup>	Document Number Number Kind Code <sup>2</sup> (if known)	Filing Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
CSO	296	60/254,465	12-08-2000	Holtzman et al.	
	297	60/254,498	12-08-2000	Holtzman et al.	
	305	09/724,842	11-28-2000	Chalfour et al.	
	295	60/184,601	02-24-2000	Holtzman et al.	
	282	60/169,687	12-08-1999	Chain	
CSO	242	60/168,594	11-29-1999	Chalfour et al.	
	283	09/441,140	11-16-1999	Solomon et al.	
CSO	299	60/186,295	03-01-2000	Rasmussen et al.	

**FOREIGN PATENT DOCUMENTS**

Examiner Initials <sup>1</sup>	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD- YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>4</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
CSO	343	EP	1 172 378	A1	01-16-2002			
	35	EP	911 036	A2	04-28-1999			
	36	EP	868 918	A2	10-07-1998			
	37	EP	863 211	A1	09-09-1998			
CSO	38	EP	845 270	A1	06-03-1998			
CSO	39	EP	782 859	A1	07-09-1997			

Examiner  
SignatureDate  
Considered

3/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60106599 v1



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 4 of 24

### Complete if Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

40	EP	683 234	A1	11-22-1995			
41	EP	666 080	A1	08-09-1995			
42	EP	652 962	B1	12-16-1998			
43	EP	639 081	B1	11-03-1999			
44	EP	613 007	A2	08-31-1994			
45	EP	594 607	B1	08-27-1997			
46	EP	561 087	B1	08-04-1999			
47	EP	526 511	B1	05-28-1997			
48	EP	506 785	B1	03-15-2000			
49	EP	451 700	A1	10-16-1991			
50	EP	440 619	B1	01-24-1996			
51	EP	359 783	B1	11-29-1995			
52	EP	276 723	B1	12-08-1993			Yes
187	EP	783 104	A1	07-09-1997			
351	WO	02/34878	A2	05-02-2002			
352	WO	02/34777	A1	05-02-2002			
341	WO	02/03911	A2	04-07-2001			
344	WO	01/90182	A2	11-29-2001			
348	WO	01/77167	A2	10-18-2001			
294	WO	01/62801	A2	08-30-2001			
301	WO	01/62284	A2	03-01-2000			
298	WO	01/42306	A2	06-14-2001			
243	WO	01/39796	A2	06-07-2001			
199	WO	00/77178	A1	12-21-2000			
322	WO	00/72880	A2, A3	12-07-2000			
323	WO	00/72876	A2, A3	12-07-2000			
324	WO	00/72870	A1	12-07-2000			
240	WO	00/43039	A1	07-27-2000			
188	WO	00/43049	A1	07-27-2000			
53	WO	99/60024	A1	11-25-1999			
54	WO	99/60021	A2	11-15-1999			
55	WO	99/58564	A1	11-18-1999			
56	WO	99/06066	A2	02-11-1999			
57	WO	99/27949	A1	06-10-1999			
58	WO	99/27944	A1	06-10-1999			

Examiner  
Signature

Date  
Considered

3/25/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* Applicant's unique citation designation number (optional). \* Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \* Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). \* For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \* Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. \* Applicant is to place a check mark here if English language translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for

Patents, Washington, DC 20231  
60106599 v1

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for Form 1449A/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet

5

of

24

Attorney Docket Number

**C mplete if Known**

Application Number

**09/724,570**

Filing Date

November 28, 2000

**First Named Inventor**

**Schenk, Dale B.**

### Art Unit

1647

**Examiner Name**

**Christopher Nichols**

Attorney Docket Number

015270-005914US

59	WO	99/27911	A1	06-10-1999			
331	WO	99/06545	A2	11-02-1999			
203	WO	99/00150	A2	01-07-1999			
60	WO	98/44955	A1	10-15-1998			
61	WO	98/07850	A2	02-26-1998			
202	WO	97/21728	A1	06-19-1997			
62	WO	97/17613	A1	05-15-1997			
383	WO	97/10505	A1	03-20-1997			
63	WO	96/39176	A1	12-12-1996			
208	WO	96/28471	A1	09-19-1996			
64	WO	96/25435	A1	08-22-1996			
65	WO	96/18900	A1	06-20-1996			
66	WO	95/31996	A1	11-30-1995			
200	WO	95/12815	A1	05-11-1995			
67	WO	95/11994	A1	05-04-1995			
68	WO	95/11311	A1	04-27-1995			
227	WO	95/11008	A2	04-27-1995			
69	WO	95/05853	A1	03-02-1995			
70	WO	95/04151	A2	02-09-1995			
201	WO	94/28412	A1	12-08-1994			
71	WO	94/03615	A1	02-17-1994			
72	WO	94/01772	A1	01-20-1994			
73	WO	93/21950	A1	11-11-1993			
74	WO	93/16724	A1	09-02-1993			
75	WO	93/15760	A1	06-19-1993			
76	WO	93/14200	A1	07-22-1993			
205	WO	93/04194	A1	03-04-1993			
77	WO	93/02189	A1	02-04-1993			
78	WO	92/13069	A1	08-06-1992			
79	WO	92/06708	A1	04-30-1992			
80	WO	92/06187	A1	04-16-1992			
81	WO	91/19810	A1	12-26-1991			
82	WO	91/16819	A1	11-14-1991			
83	WO	91/12816	A1	09-05-1991			
84	WO	91/08760	A1	06-27-1991			

**Examiner  
Signature**

Date Considered


$$3/25/04$$

**EXAMINER:** Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 601.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231**

60106599 v1



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 6 of 24

### Complete if Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

85	WO	90/12871	A1	11-01-1990			
86	WO	90/12870	A1	11-01-1990			
87	WO	89/01343	A1	02-23-1989			
88	WO	89/06242	A1	07-13-1989			
89	WO	89/06689	A1	07-27-1989			
90	WO	89/03687	A1	05-05-1989			
91	WO	88/10120	A1	12-29-1988			
92	GB	2 220 211	A	01-04-1990			
93	GB	2 335 192	A	09-15-1999			

Examiner  
Signature

*[Signature]*


Date  
Considered

3/25/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Kind Codes of U.S. Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,570		
		Filing Date	November 28, 2000		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1647		
		Examiner Name	Christopher Nichols		
Sheet	7	of	24	Attorney Docket Number	015270-005914US

OTHER PRIOR ART – NON PATENT LITERATURE DOCUMENTS			
Examiner Initials *	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	391	AGUZZI et al., "Prion research: the next frontiers," <u>Nature</u> , 389:795-798 (1997).	<input type="checkbox"/>
	393	AKIYAMA et al., "Inflammation and Alzheimer's disease," <u>Neurobiology of Aging</u> , 21:383-421 (2000).	<input type="checkbox"/>
	372	AKIYAMA et al., "Occurrence of the Diffuse Amyloid $\beta$ -Protein (A $\beta$ ) Deposits With Numerous A $\beta$ -Containing Glial Cells in the Cerebral Cortex of Patients With Alzheimer's Disease," <u>Glia</u> , 25:324-331 (1999).	<input type="checkbox"/>
	94	ANDERSEN et al., "Do nonsteroidal anti-inflammatory drugs decrease the risk for Alzheimer's disease?", <u>Neurology</u> , 45:1441-1445 (1995).	<input type="checkbox"/>
	95	Associated Press, "Immune cells may promote Alzheimer's, a study finds," <u>The Boston Globe</u> (4/13/95).	<input type="checkbox"/>
	176	BARD et al., "Peripherally administered antibodies against amyloid $\beta$ -peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease," <u>Nature Medicine</u> , 6(8):916-919 (2000).	<input type="checkbox"/>
	228	BARROW et al., "Solution Conformations and aggregational Properties of Synthetic Amyloid Beta-Peptides of Alzheimer's Disease. Analysis of Circular Dichroism Spectra," <u>J. Mol. Biol.</u> , 225(4): 1075-1093 (1992).	<input type="checkbox"/>
	96	BAUER et al., "Interleukin-6 and $\alpha$ -2-macroglobulin indicate an acute-phase state in Alzheimer's disease cortices," <u>FEBS Letters</u> , 285(1):111-114 (1991).	<input type="checkbox"/>
	239	BEASLEY, "Alzheimer's traced to proteins caused by aging," Reuters, April 20, 2001 7:56 PM ET.	<input type="checkbox"/>
	404	BENJAMINI and LESKOWITZ, from <u>IMMUNOLOGY A Short Course</u> , Second Edition, Chapter 4, Antibody Structure, pages 49-65, 1991, published by Wiley-Liss, Inc., New York, New York.	<input type="checkbox"/>
	204	BERCOVICI et al., "Chronic Intravenous Injections of Antigen Induce and Maintain Tolerance in T Cell Receptor-Transgenic Mice," <u>Eur. J. Immunol.</u> , 29:345-354 (1999).	<input type="checkbox"/>
	212	BICKEL et al., "Site Protected, Cationized Monoclonal Antibody Against Beta Amyloid as a Potential Diagnostic Imaging Technique for Alzheimer's Diseases," <u>Soc. for Neuroscience Abstracts</u> , 18:764 (1992).	<input type="checkbox"/>

Examiner Signature		Date Considered	3/25/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 24

### Complete if Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

CSO	97	BLASS, "Immunologic Treatment of Alzheimer's Disease," <u>New England J. Medicine</u> , 341(22):1694 (1999).	<input checked="" type="checkbox"/>
	98	BODMER et al., "Transforming Growth Factor-Beta Bound to Soluble Derivatives of the Beta Amyloid Precursor Protein of Alzheimer's Disease," <u>Biochem. Biophys. Res. Comm.</u> , 171(2):890-897 (1990).	<input checked="" type="checkbox"/>
	99	BORCHELT et al., "Accelerated Amyloid Deposition in the Brains of Transgenic Mice Coexpressing Mutant Presenilin 1 and Amyloid Precursor Proteins," <u>Neuron</u> , 19: 939-945 (1997).	<input checked="" type="checkbox"/>
	100	BORIS-LAWRIE et al., "Recent advances in retrovirus vector technology," <u>Cur. Opin. Genetic Develop.</u> , 3: 102-109 (1993).	<input checked="" type="checkbox"/>
	101	BRICE et al., "Absence of the amyloid precursor protein gene mutation (APP717 : Val->Ile) in 85 cases of early onset Alzheimer's disease," <u>J. Neurology, Neurosurg. Psychiatry</u> , 56:112-115 (1993).	<input checked="" type="checkbox"/>
	327	CAMERON, "Recent Advances in Transgenic Technology," <u>Molecular Biotechnology</u> , 7:253-265 (1997).	<input checked="" type="checkbox"/>
	285	CAPUTO et al., "Therapeutic approaches targeted at the amyloid proteins in Alzheimer's disease," <u>Clin. Neuropharm.</u> , 15:414A-414B (1992).	<input checked="" type="checkbox"/>
	224	Center for Biologics Evaluation and Research, U.S. Food and Drug Administration, Thimerosal in Vaccines (Mercury in Plasma-Derived Products), web site contents found at : <a href="http://www.fda.gov/cber/vaccine/thimerosal.htm">http://www.fda.gov/cber/vaccine/thimerosal.htm</a> , last updated May 16, 2002.	<input checked="" type="checkbox"/>
	102	CHAO et al., "Transforming Growth Factor- $\beta$ Protects human Neurons Against $\beta$ -Amyloid-Induced Injury," <u>Soc. Neurosci. Abstracts</u> , 19:513-7 (1993).	<input checked="" type="checkbox"/>
	266	CHAPMAN, "Model behavior," <u>Nature</u> , 408:915-916 (2000).	<input checked="" type="checkbox"/>
CSO	349	CHECK, "Battle of the Mind," <u>Nature</u> , 422:370-372 (March 2003).	<input checked="" type="checkbox"/>
	222	Chemical Abstract database, Abstract of "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologics," <u>Chemical Abstract database</u> . (Publication date unknown.)	<input checked="" type="checkbox"/>
CSO	332	CHEN et al., "Neurodegenerative Alzheimer-like pathology in PDAPP 717V $\rightarrow$ F transgenic mice," <u>Progress in Brain Research</u> , Van Leeuwen et al. Eds, 117:327-337 (1998).	<input checked="" type="checkbox"/>
CSO	213	CHEN et al., "An Antibody to $\beta$ Amyloid Precursor Protein Inhibits Cell-substratum Adhesion in Many Mammalian Cell Types," <u>Neuroscience Letters</u> , 125:223-226 (1991).	<input checked="" type="checkbox"/>

Examiner  
Signature

*G. M. [Signature]*

Date  
Considered

3/25/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/724,570
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher Nichols
		Attorney Docket Number	015270-005914US

Sheet 9 of 24


307	CHEN et al., "A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease," <u>Nature</u> , 408(6815):975-9 (2000).	—
302	CHUNG et al., "Uptake, Degradation, and Release of Fibrillar and Soluble Forms of Alzheimer's Amyloid $\beta$ -Peptide by Microglial Cells," <u>J. Biol. Chem.</u> , 274(45):32301-32308 (1999).	—
291	COLOMA et al., "Transport Across the Primate Blood-Brain Barrier of a Genetically Engineered Chimeric Monoclonal Antibody to the Human Insulin Receptor," <u>Pharm. Res.</u> , 17:266-274 (2000).	—
333	CONWAY et al., "Acceleration of oligomerization, not fibrillization, is a shared property of both $\alpha$ -synuclein mutations linked to early-onset Parkinson's disease: Implications for pathogenesis and therapy," <u>PNAS</u> , 97(2):571-576 (2000)	—
286	CORDELL, B., " $\beta$ -Amyloid formation as a potential therapeutic target for Alzheimer's disease," <u>Ann. Rev. Pharmacol. Toxicol.</u> , 34:69-89 (1994).	—
287	COSTA et al., "Immunoassay for transthyretin variants associated with amyloid neuropathy," <u>Scand. J. Immunol.</u> , 38:177-182 (1993).	—
293	DALY, et al., "Detection of the membrane-retained carboxy-terminal tail containing polypeptides of the amyloid precursor protein in tissue from Alzheimer's Disease brain," <u>Life Sci.</u> , 63:2121-2131 (1998).	—
214	DEMATTOS et al., "Peripheral Anti A $\beta$ Antibody Alters CNS And Plasma A $\beta$ Clearance and Decreases Brain A $\beta$ Burden in a Mouse Model of Alzheimer's Disease," <u>Proc. Natl. Acad. Sci. USA</u> , 10.1073/pnas.151261398 (2001).	—
220	<del>Dialog/Derwent, Abstract of WPI Acc No: 1997-054436/199706. Stable vaccine compns: — comprise a macrocyclic lactone, a milbemycin, an avermectin, an antigen, a dispersing agent, an adjuvant, a water-sol. organic solvent and saline or water, Derwent File 351; Derwent WPI database. (Publication date unknown).</del>	—
390	DIOMEDE et al., "Activation effects of a prion protein fragment [PrP-(106-126)] on human leucocytes," <u>Biochem. J.</u> , 320:563-570 (1996).	—
363	DODART, "Immunotherapy for Alzheimer's disease: will vaccination work?" <u>Trends in Molecular Medicine</u> , 9(3):85-87 (2003).	—
318	DU et al., "Reduced levels of amyloid beta-peptide antibody in Alzheimer disease," <u>Neurology</u> , 57(5):801-5 (2001).	—
103	DUFF et al., "Mouse model made," <u>Nature</u> , 373: 476-477 (1995).	—

Examiner Signature		Date Considered	3/25/04
--------------------	--	-----------------	---------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/724,570
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher Nichols
		Attorney Docket Number	015270-005914US

Sheet	10	of	24
-------	----	----	----

288	DUMERY et al., "β-Amyloid protein aggregation: its implication in the physiopathology of Alzheimer's disease," <u>Pathol. Biol.</u> , 49:72-85 (2001).	—
407	ECK et al., <u>Goodman and Gilman's The pharmacological basis of therapeutics</u> , Chapter 5, pages 77-101 (1996)	—
225	Elan, "Elan and AHP Provide an Update on the Phase 2A Clinical Trial of AN-1792," Press Release. (1/18/2002).	—
226	Elan, "Elan and Wyeth Provide Update on Status of Alzheimer's Collaboration," Press Release (3/1/2002)	—
104	ELIZAN et al., "Antineurofilament antibodies in a postencephalitic and idiopathic Parkinson's disease," <u>J. Neurol. Sciences</u> , 59:341-347 (1983).	—
289	ESIRI, "Is an effective immune intervention for Alzheimer's disease in prospect?", <u>Trends in Pharm. Sci.</u> , 22:2-3 (2001).	—
105	FELSENSTEIN et al., "Processing of the β-amyloid precursor protein carrying the familial, Dutch-type, and a novel recombinant C-terminal mutation," <u>Neuroscience Letters</u> , 152:185-189 (1993).	—
328	FELSENSTEIN et al., "Transgenic Rat and In-Vitro Studies of β-Amyloid Precursor Protein Processing," <u>Alzheimer's and Parkinson's Diseases</u> , Hanin et al. Ed., pp 401-409, Plenum Press, New York, (1995).	—
106	FINCH et al., "Evolutionary Perspectives on Amyloid and Inflammatory Features of Alzheimer Disease," <u>Neurobiology of Aging</u> , 17(5):809-815 (1996).	—
107	FISHER et al., "Expression of the amyloid precursor protein gene in mouse oocytes and embryos," <u>PNAS</u> , 88:1779-1782 (1991).	—
108	FLANDERS et al., "Altered expression of transforming growth factor-β in Alzheimer's disease," <u>Neurology</u> , 45:1561-1569 (1995).	—
386	FRAUTSCHY et al., "Effects of injected Alzheimer β-amyloid cores in rat brain," <u>PNAS</u> , 88:8362-8366 (1991).	—
246	FRENKEL et al., "Generation of auto-antibodies towards Alzheimer's disease vaccination," <u>Vaccine</u> , 19:2615-2619 (2001).	—

Examiner Signature		Date Considered	3/25/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 11

of

24

### Complete if Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

245	FRENKEL et al., "High affinity binding of monoclonal antibodies to the sequential epitope EFRH of $\beta$ -amyloid peptide is essential for modulation of fibrillar aggregation," <u>J. of Neuroimmunology</u> , 95:136-142 (1999).
247	FRENKEL et al., "Immunization against Alzheimer's $\beta$ -amyloid plaques via EFRH phage administration," <u>PNAS USA</u> , 97:11455-11459 (2000).
248	FRENKEL et al., "N-terminal EFRH sequence of Alzheimer's $\beta$ -amyloid peptide represents the epitope of its anti-aggregating antibodies," <u>J. of Neuroimmunology</u> , 88:85-90 (1998).
244	FRENKEL, et al., "Modulation of Alzheimer's $\beta$ -amyloid neurotoxicity by site-directed single chain antibody," <u>J. of Neuroimmunology</u> , 106:23-31 (2000).
210	FRIEDLAND et al., "Development of an anti-A $\beta$ monoclonal antibody for in vivo imaging of amyloid angiopathy in Alzheimer's disease," <u>Mol. Neurology</u> , 9:107-113 (1994).
249	FRIEDLAND, et al., "Neuroimaging of Vessel Amyloid in Alzheimer's Disease," in <u>Cerebrovascular Pathology in Alzheimer's Disease</u> , eds. de la Torre and Hachinski, New York Academy of Sciences, New York, New York (1997).
364	FURLAN et al., "Vaccination with amyloid- $\beta$ peptide induces autoimmune encephalomyelitis in C57/BL6 mice," <u>Brain</u> , 126:285-291 (2003).
109	GAMES et al., "Alzheimer-type neuropathology in transgenic mice overexpressing V717F $\beta$ -amyloid precursor protein," <u>Nature</u> , 373(6514): 523-527 (1995).
215	GAMES et al., "Prevention and Reduction of AD-type Pathology in PDAPP Mice Immunized with A $\beta_{1-42}$ ," <u>Annals of the New York Academy of Science</u> 920:274-84 (2000).
110	GANDY et al., "Amyloidogenesis in Alzheimer's disease: some possible therapeutic opportunities," <u>TIPS</u> , 13:108-113 (1992).
251	GARDELLA et al., "Intact Alzheimer amyloid precursor protein (APP) is present in platelet membranes and is encoded by platelet mRNA," <u>Biochem. Biophys. Res. Comm.</u> , 173:1292-1298 (1990).
111	GASKIN et al., "Human antibodies reactive with beta-amyloid protein in Alzheimer's disease," <u>J. Exp. Med.</u> , 177:1181-1186 (1993).
252	GEDDES, "N-terminus truncated $\beta$ -amyloid peptides and C-terminus truncated secreted forms of amyloid precursor protein: distinct roles in the pathogenesis of Alzheimer's disease," <u>Neurobiology of Aging</u> , 20:75-79 (1999).

Examiner  
Signature

Date  
Considered

3/25/04

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

\* Applicant's unique citation designation number (optional). \* Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,570		
		Filing Date	November 28, 2000		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1647		
		Examiner Name	Christopher Nichols		
Sheet	12	of	24	Attorney Docket Number	015270-005914US

253	GIULIAN, et al., "The HHQK Domain of b-Amyloid Provides a Structural Basis for the Immunopathology of Alzheimer's Disease," <u>Journal of Biological Chem.</u> , 273:29719-29726 (1998).	—
112	GLENN et al., "Skin immunization made possible by cholera toxin," <u>Nature</u> , 391: 851 (1998).	—
114	GLENNER et al., "Alzheimer's Disease and Downs Syndrome: Sharing of A Unique Cerebrovascular Amyloid Fibril Protein," <u>Biochemical and Biophysical Research Communications</u> , 122(3): 1131-1135 (1984).	—
113	GLENNER et al., "Alzheimer's Disease: Initial Report of the Purification and Characterization of a Novel Cerebrovascular Amyloid Protein," <u>Biochemical and Biophysical Research Communications</u> , 120(3): 885-890 (1994).	—
115	GOATE et al., "Segregation of a missense mutation in the amyloid precursor protein gene with familial Alzheimer's disease," <u>Nature</u> , 349:704-706 (1991).	—
388	GOLDFARB et al., "The Transmissible Spongiform Encephalopathies," <u>Ann. Rev. Med.</u> , 46:57-65 (1995).	—
397	GOLDSTEINS et al., "Goldsteins et al., Exposure of cryptic epitopes on transthyretin only in amypoid and in amyloidogenic mutants," <u>PNAS</u> , 96:3108-3113 (1999).	—
303	GONZALES-FERNANDEZ et al., "Low antigen dose favors selection of somatic mutants with hallmarks of antibody affinity maturation," <u>Immunology</u> , 93:149-153 (1998).	—
237	GORTNER, <u>Outlines of Biochemistry</u> , pp. 322-323, John Wiley & Sons, Inc., New York (1949).	—
116	GOZES et al., "Neuroprotective strategy for Alzheimer disease: Intranasal administration of a fatty neuropeptide," <u>PNAS USA</u> , 93:427-432 (1996).	—
190	GRAVINA et al., "Amyloid $\beta$ Protein ( $A\beta$ ) in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 270(13):7013-7016 (1995).	—
254	GRUBECK-LOEBENSTEIN, et al., "Immunization with $\beta$ -amyloid: could T-cell activation have a harmful effect?", <u>TINS</u> , 23:114 (2000).	—
117	GUPTA et al., "Differences in the immunogenicity of native and formalized cross reacting material (CRM197) of diphtheria toxin in mice and guinea pigs and their implications on the development and control of diphtheria vaccine based on CRMs," <u>Vaccine</u> , 15(12/13): 1341-1343 (1997).	—
241	HAASS et al. "Amyloid beta-peptide is produced by cultured cells during normal metabolism," <u>Nature</u> , 359(6393):322-5 (1992).	—

Examiner Signature		Date Considered	3/25/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 13 of 24

### Complete if Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

118	HAGA et al., "Synthetic Alzheimer amyloid $\beta$ /A4 peptides enhance production of complement C3 component by cultured microglial cells," <u>Brain Research</u> , 601:88-94 (1993).	—
182	HANAN and SOLOMON, "Inhibitory effect of monoclonal antibodies on Alzheimer's $\beta$ -amyloid peptide aggregation," <u>Int. J. Exp. Clin. Invest.</u> , 3:130-133 (1996).	—
119	HANES et al., "New advances in microsphere-based single-dose vaccines," <u>Advanced Drug Delivery Reviews</u> , 28: 97-119 (1997).	—
120	HARDY, "Amyloid, the presenilins and Alzheimer's disease," <u>TINS</u> , 20(4): 154-159 (1997).	—
121	HARDY, John, "New Insights Into the Genetics of Alzheimer's Disease," <u>Annals of Med.</u> , 28:255-258 (1996).	—
255	HARIGAYA, et al., "Modified amyloid $\beta$ protein ending at 42 or 40 with different solubility accumulates in the brain of Alzheimer's disease," <u>Biochem. Biophys. Res. Comm.</u> , 211:1015-1022 (1995).	—
193	HARRINGTON et al., "Characterization of an epitope specific to the neuron-specific isoform of human enolase recognized by a monoclonal antibody raised against a synthetic peptide corresponding to the C-terminus of $\beta$ /A4-protein," <u>Biochimica Biophysica Acta</u> , 1158:120-128 (1993).	—
229	HAZAMA, et al., "Intranasal Immunization Against Herpes Simplex Virus Infection by Using a Recombinant Glycoprotein D Fused With Immunomodulating Proteins, the B Subunit of Escherichia Coli Heat-Labile Enterotoxin and Interleukin-2," <u>Immunology</u> , Vol. 78: 643-649 (1993).	—
177	HELMUTH, "Further Progress on a $\beta$ -Amyloid Vaccine," <u>Science</u> , 289:375 (2000).	—
236	HILBICH et al., "Human and rodent sequence analogs of Alzheimer's amyloid $\beta$ A4 share similar properties and can be solubilized in buffers of pH 7.4," <u>Eur. J. Biochem.</u> , 201:61-69 (1991).	—
122	HSIAO et al., "Correlative Memory Deficits, A $\beta$ Elevation, and Amyloid Plaques in Transgenic Mice," <u>Science</u> , 274: 99-102 (1996).	—
123	HUBERMAN et al., "Correlation of cytokine secretion by mononuclear cells of Alzheimer's patients and their disease stage," <u>J. Neuroimmunology</u> , 52:147-152 (1994).	—
174	Human Immunology & Cancer Program brochure, from The University of Tennessee Medical Center/ Graduate School of Medicine, Knoxville, Tennessee (publication date unknown).	—
124	HYMAN et al., "Molecular Epidemiology of Alzheimer's Disease," <u>N. E. J. Medicine</u> , 333(19):1283-1284 (1995).	—

Examiner  
Signature

*[Signature]*

Date  
Considered

3/24/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>	
		Application Number	09/724,570
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher Nichols
Sheet 14 of 24	Attorney Docket Number	015270-005914US	


256	IKEDA, et al., "Immunogold labeling of cerebrovascular and neuritic plaque amyloid fibrils in Alzheimer's disease with an anti- $\beta$ protein monoclonal antibody," <u>Lab. Invest.</u> , 57:446-449 (1987).	—
125	ITAGAKI et al., "Relationship of microglia and astrocytes to amyloid deposits of Alzheimer's disease," <u>J. Neuroimmunology</u> , 24:173-182 (1989).	—
192	IWATSUBO et al., "Visualization of A $\beta$ 42(43) and A $\beta$ 40 in Senile Plaques with End-Specific A $\beta$ Monoclonals: Evidence That an Initially Deposited Species Is A $\beta$ 42(43)," <u>Neuron</u> , 13:45-53 (1994).	—
374	JAKES et al., "Characterisation of an Antibody Relevant to the Neuropathology of Alzheimer Disease," <u>Alzheimer Disease and Associated Disorders</u> , 9(1):47-51, Raven Press, Ltd., New York (1995).	—
126	JANSEN et al., "Immunotoxins: Hybrid Molecules Combining High Specificity and Potent Cytotoxicity," <u>Immun. Rev.</u> , 62: 185-216 (1982).	—
308	JANUS et al., "A beta peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease," <u>Nature</u> , 408(6815):979-82 (2000).	—
257	JEN, et al., "Preparation and purification of antisera against different regions or isoforms of b-amyloid precursor protein," <u>Brain Research Protocols</u> , 2:23-30 (1997).	—
216	JOACHIM et al., "Antibodies to Non-beta Regions of the Beta-amyloid Precursor Protein Detect a Subset of Senile Plaques," <u>Am. J. of Pathology</u> , 138:373-384 (1991).	—
334	JOBLING and HOLMES, "Analysis of structure and function of the B subunit of cholera toxin by the use of site-directed mutagenesis," <u>Molecular Microbiology</u> , 5(7):1755-1767 (1991).	—
371	JOHNSTONE et al., Nuclear and Cytoplasmic Localization of the $\beta$ -Amyloid Peptide (1-43) in Transfected 293 Cells," <u>Biochemical and Biophysical Research Communications</u> , 220:710-716 (1996).	—
347	JORBECK et al., "Artificial Salmonella Vaccines: <i>Salmonella typhimurium</i> O-antigen-Specific Oligosaccharide-Protein Conjugates Elicit Opsonizing Antibodies that Enhance Phagocytosis," <u>Infection and Immunity</u> , May:497-502 (1981).	—
127	KALARIA, R. N., "Serum amyloid P and related molecules associated with the acute-phase response in Alzheimer's disease," <u>Res. Immunology</u> , 143:637-641 (1992).	—
183	KATZAV-GOZANSKY et al., "Effect of monoclonal antibodies in preventing carboxypeptidase A aggregation," <u>Biotechnol. Appl. Biochem.</u> , 23:227-230 (1996).	—

Examiner Signature	<i>g. nichols</i>	Date Considered	3/25/04
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet 15 of 24

**Complete if Known**

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

128	KAWABATA et al., "Amyloid plaques, neurofibrillary tangles and neuronal loss in brains of transgenic mice overexpressing a C-terminal fragment of human amyloid precursor protein," <u>Nature</u> , 354:476-478 (1991).
258	KIDA, et al., "Early amyloid- $\beta$ deposits show different immunoreactivity to the amino- and carboxy-terminal regions of b-peptide in Alzheimer's disease and Down's syndrome brain," <u>Neuroscience Letters</u> , 193:105-108 (1995).
195	KONIG et al., "Development and Characterization of a Monoclonal Antibody 369.28 Specific for the Carboxyl-Terminus of the $\beta$ A4 Peptide," <u>Annals of NY Acad. Sci.</u> , 777:344-355 (1996).
389	KOVÁCS et al., "Mutations of the Prion Protein Gene Phenotypic Spectrum," <u>J. Neurol.</u> , 249:1567-1582 (2002).
129	LAMPERT-ETCHELLS et al., "Regional Localization of Cells Containing Complement C1q and C4 mRNAs in the Frontal Cortex During Alzheimer's Disease," <u>Neurodegeneration</u> , 2:111-121 (1993).
130	LANGER, "New Methods of Drug Delivery," <u>Science</u> , 249: 1527-1532 (1990).
131	LANNFELT et al., "Alzheimer's disease: molecular genetics and transgenic animal models," <u>Behavioural Brain Res.</u> , 57:207-213 (1993).
259	LANSBURY, PETER T., "Inhibition of amyloid formation: a strategy to delay the onset of Alzheimer's disease," <u>Curr. Ops. in Chemical Biology</u> , 1:260-267 (1997).
132	LEMERE et al., "Mucosal Administration of A $\beta$ Peptide Decreases Cerebral Amyloid Burden in Pd-App Transgenic Mice," <u>Society for Neuroscience Abstracts</u> , vol. 25, part 1, Abstract 519.6, 29th Annual Meeting, (October 23-28, 1999).
260	LEMERE, et al., "Nasal A $\beta$ treatment induces anti-A $\beta$ antibody production and decreases cerebral amyloid burden in PD-APP mice," <u>Annals of the NY Acad. Sci.</u> , 920:328-331 (2000).
184	LI and SOLOMON, "Thermal Stabilization of Carboxypeptidase A as a Function of PH and Ionic Milieu," <u>Biochem. Mol. Biol. Int.</u> , 43(3):601-611 (1997).
133	LIVINGSTON et al., "The Hepatitis B Virus-Specific CTL Responses Induced in Humans by Lipopeptide Vaccination Are Comparable to Those Elicited by Acute Viral Infection," <u>J. Immunol.</u> , 159: 1383-1392 (1997).
134	LOPEZ et al., "Serum auto-antibodies in Alzheimer's disease," <u>Acta. Neurol. Scand.</u> , 84:441-444 (1991).

Examiner  
SignatureDate  
Considered

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

60106599 v1





Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 16

of 24

### Complete if Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

218	MAJOCHA et al., "Development of a Monoclonal Antibody Specific for $\beta$ /A4 Amyloid in Alzheimer's Disease Brain for Application to In Vitro Imaging of Amyloid Angiopathy," <u>The J. of Nuclear Med.</u> 33:2184-2189 (1992).	—
261	MAK, et al., "Polyclonals to b-amyloid (1-42) identify most plaque and vascular deposits in Alzheimer cortex, but not striatum," <u>Brain Research</u> , 667:138-142 (1994).	—
263	MANN, et al., "Amyloid $\beta$ protein ( $A\beta$ ) deposition in chromosome 14-linked Alzheimer's disease: Predominance of $A\beta_{42/43}$ ," <u>Annals of Neurology</u> , 40:149-156 (1996).	—
262	MANN, et al., "The extent of amyloid deposition in brain in patients with Down's syndrome does not depend upon the apolipoprotein E genotype," <u>Neuroscience Letters</u> , 196:105-108 (1995).	—
408	MARSHALL, E., "Gene Therapy's Growing Pains," <u>Science</u> , 269:1050-1055 (1995).	—
335	MASLIAH et al., " $\beta$ -Amyloid peptides enhance $\alpha$ -synuclein accumulation and neuronal deficits in a transgenic mouse model linking Alzheimer's disease and Parkinson's disease," <u>PNAS</u> , 98(21):12245-12250 (2001).	—
217	MASTERS et al., "Amyloid Plaque core protein in Alzheimer Disease and Down Syndrome," <u>Proc. Natl. Acad. Sci. USA</u> , 82:4245-4249 (1985).	—
309	MATTSON, Cellular actions of beta-amyloid precursor protein and its soluble and fibrillogenic derivatives. <u>Physiol Rev.</u> 77(4):1081-132 (1997).	—
135	MC GEE et al., "The encapsulation of a model protein in poly (D, L lactide-co-glycolide) microparticles of various sizes: an evaluation of process reproducibility," <u>J. Micro. Encap.</u> , 14(2): 197-210 (1997).	—
264	MC GEEER, et al., "Immunohistochemical localization of beta-amyloid precursor protein sequences in Alzheimer and normal brain tissue by light and electron microscopy," <u>J. of Neuroscience Res.</u> , 31:428-442 (1992).	—
238	MCNEAL et al., "Stimulation of local immunity and protection in mice by intramuscular immunization with triple- or double-layered rotavirus particles and QS-21," <u>Virology</u> , 243:158-166 (1998).	—
136	MEDA et al., "Activation of microglial cells by $\beta$ -amyloid protein and interferon- $\gamma$ ," <u>Nature</u> , 374:647-650 (1995).	—
265	MENA, et al., "Monitoring pathological assembly of tau and $\beta$ -amyloid proteins in Alzheimer's disease," <u>Acta Neuropathol.</u> , 89:50-56 (1995).	—

Examiner  
Signature

*g. nichols*


Date  
Considered

3/25/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449B/PTO		<b>Complete if Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,570
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher Nichols
Sheet 17 of 24	Attorney Docket Number	015270-005914US	


310	MERLUZZI, et al., "Humanized antibodies as potential drugs for therapeutic use," <u>Adv Clin Path.</u> , 4(2):77-85 (2000).
137	MILLER et al., "Antigen-driven Bystander Suppression after Oral Administration of Antigens," <u>J. Exp. Med.</u> , 174:791-798 (1991).
367	MONSONEGO et al., "Immune hyporesponsiveness to amyloid $\beta$ -peptide in amyloid precursor protein transgenic mice: Implications for the pathogenesis and treatment of Alzheimer's disease," <u>PNAS</u> , 98(18):10273-10278 (2001).
311	MORGAN, et al., "A beta peptide vaccination prevents memory loss in an animal model of Alzheimer's disease," <u>Nature</u> , 408(6815):982-5 (2000).
206	MORI et al., "Mass Spectrometry of Purified Amyloid $\beta$ Protein in Alzheimer's Disease," <u>J. Biol. Chem.</u> , 267(24):17082-17088 (1992).
233	MORRIS, et al., "The Consortium to Establish a registry for Alzheimer's Disease (CERAD)," <u>Neurology</u> , 39:1159-65 (1989).
359	MUNCH et al., "Potential neurotoxic inflammatory response to A $\beta$ vaccination in humans," (2002) <u>J. Neural Transm.</u> , 109:1081-1087.
355	MUNSON ed., "Principals of Pharmacology: Basic Concepts & Clinical Applications," (1995), 47-48, Chapman & Hall, New York, New York.
191	MURPHY et al., "Development of a Monoclonal Antibody Specific for the COOH-Terminal of $\beta$ -Amyloid 1-42 and Its Immunohistochemical Reactivity in Alzheimer's Disease and Related Disorders," <u>Am. J. Pathology</u> , 144(5):1082-1088 (1994).
354	MUTSCHLER et al., "Drug Actions: Basic Principles and Therapeutic Aspects," (1995) 7, 11-12, medpharm Scientific Publishers, Stuttgart, Germany.
250	NAKAMURA et al., "Histopathological studies on senile plaques and cerebral amyloid angiopathy in aged cynomolgus monkeys," <u>Exp. Anim.</u> , 43:711-718 (1995).
268	NAKAMURA, et al., "Carboxyl end-specific monoclonal antibodies to amyloid $\beta$ protein (A $\beta$ ) subtypes (A $\beta$ 40 and A $\beta$ 42(43) differentiate Ab in senile plaques and amyloid angiopathy in brains of aged cynomolgus monkeys," <u>Neuroscience Letters</u> , 201:151-154 (1995).
281	NAKAYAMA et al., "Histopathological studies of senile plaques and cerebral amyloidosis in cynomolgus monkeys," <u>J. of Med. Primatology</u> , 27:244-252 (1998).

Examiner Signature		Date Considered	3/25/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,570
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher Nichols
		Attorney Docket Number	015270-005914US
Sheet	18	of	24


138	NATHANSON et al., "Bovine Spongiform Encephalopathy (BSE): Causes and Consequences of a Common Source Epidemic," <u>Am. J. Epidemiol.</u> , 145(11): 959-969 (June 1, 1997).	✓
139	New York Times National, "Anti-Inflammatory Drugs May Impede Alzheimer's," (2/20/94).	✓
235	NEWCOMBE and COHEN, "Solubility characteristics of isolated amyloid fibrils," <u>Biochim. Biophys. Acta</u> , 104:480-486 (1965).	✓
350	NICOLL et al., "Neuropathology of human Alzheimer's disease after immunization with amyloid- $\beta$ peptide: a case report," <u>Nature Medicine</u> , 9(4):448-452 (April 2003).	✓
329	NIEMANN, "Transgenic farm animals get off the ground," <u>Transgenic Research</u> 7:73-75 (1998).	✓
409	ORKIN et al., <i>Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy</i> , December 7, 1995	✓
398	PALHA et al., "Antibody recognition of amyloidogenic transthyretin variants in serum of patients with familial amyloidotic polyneuropathy," <u>J. Mol. Med.</u> , 7:703-707 (2001).	✓
406	PAN et al., "Antibodies to $\beta$ -Amyloid Decrease the Blood-to-Brain Transfer of $\beta$ -Amyloid Peptide," <u>Exp. Biol. Med.</u> , 227(8):609-615 (2002).	✓
280	PARDRIDGE et al., "Chimeric peptides as a vehicle for peptide pharmaceutical delivery through the blood-brain barrier," <u>Biochem. Biophys. Res. Comm.</u> , 146:307-313 (1987).	✓
140	PARESCIE et al., "Microglial cells influence aggregates of the Alzheimer's disease amyloid beta-protein via a scavenger receptor," <u>Neuron</u> , 17:553-565 (September 1996).	✓
141	PAUL et al., "Transdermal immunization with large proteins by means of ultraformable drug carriers," <u>Eur. J. Immunol.</u> , 25: 3521-3524 (1995).	✓
336	PERUTZ et al., "Amyloid fibers are water-filled nanotubes," <u>PNAS</u> , 99(8):5591-5595 (2002).	✓
232	PETERSON, et al., "Recombinant Antibodies: Alternative Strategies for Developing and Manipulating Murine-Derived Monoclonal Antibodies," <u>Laboratory Animal Science</u> , 46(1):8-14 (1996).	✓
269	PHILIPPE, et al. "Generation of a monoclonal antibody to the carboxy-terminal domain of tau by immunization with the amino-terminal domain of the amyloid precursor protein," <u>J. of Neuroscience Res.</u> , 46:709-719 (1996).	✓
142	PRIEELS et al., "Synergistic adjuvants for vaccines," <u>Chemical Abstracts</u> , 120(8): pg. 652, column 1, abstract 86406i (1994).	✓

Examiner Signature	<i>C. Nichols</i>	Date Considered	3/25/04
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete if Known</b>			
		Application Number	09/724,570		
		Filing Date	November 28, 2000		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1647		
		Examiner Name	Christopher Nichols		
Sheet	19	of	24	Attorney Docket Number	015270-005914US

394	PRUSINER et al., "Ablation of the prion protein (PrP) gene in mice prevents scrapie and facilitates production of anti-PrP antibodies," <u>PNAS</u> , 90:10608-10612 (1993).	
143	QUON et al., "Formation of $\beta$ -Amyloid protein deposits in brains of transgenic mice," <u>Nature</u> , 352:239-241 (1991).	
145	RASO, "Immunotherapy of Alzheimer's Disease," <u>Immunotherapy Weekly</u> , Abstract (April 2, 1998).	
<del>304</del>	<del>RASO, V.A., Grant application # 1-R43-AG-5746-01 (non-redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).</del>	
<del>144</del>	<del>RASO, V.A., Grant application # 1-R43-AG-5746-01 (redacted version), "Immunotherapy of Alzheimer's Disease" (publication date unknown).</del>	
146	ROGERS et al., "Complement activation by $\beta$ -amyloid in Alzheimer Disease," <u>PNAS</u> , 89:1-5 (1992).	
147	ROSSOR et al., "Alzheimer's Disease Families with Amyloid Precursor Protein Mutations," <u>Annals of New York Academy of Sciences</u> , 695:198-202 (1993).	
209	RUDINGER, "Characteristics of the Amino Acids as Components of a Peptide Hormone Sequence," in <u>Peptide Hormones</u> , J.A. Parson, ed. University Park Press, Baltimore, pp 1-7 (1976).	
189	SAIDO et al., "Spatial Resolution of Fodrin Proteolysis in Postischemic Brain," <u>J. Biol. Chem.</u> , 268(33):25239-25243 (1993).	
194	SAIDO et al., "Spatial Resolution of the Primary $\beta$ -Amyloidogenic Process Induced in Postischemic Hippocampus," <u>J. Biol. Chem.</u> , 269(21):15253-15257 (1994).	
279	SAITO et al., "Vector-mediated delivery of $^{125}$ I-labeled $\beta$ -amyloid peptide Ab $^{1-40}$ through the blood-brain barrier and binding to Alzheimer disease amyloid of the A $\beta^{1-40}$ vector complex," <u>PNAS USA</u> , 92:10227-10231 (1995)."	
278	SAITOH, N. et al., "Immunological analysis of Alzheimer's disease using anti- $\beta$ -protein monoclonal antibodies," <u>Sapporo Med. J.</u> , 60:309-320 (1991).	
277	SASAKI et al., "Human choroid plexus is an uniquely involved area of the brain in amyloidosis: a histochemical, immunohistochemical and ultrastructural study," <u>Brain Res.</u> , 755:193-201 (1997).	
148	SCHENK et al., "Immunization with amyloid- $\beta$ attenuates Alzheimer-disease-like pathology in the PDAPP mouse," <u>Nature</u> , 400:173-177 (1999).	

Examiner Signature	<i>G. Nichols</i>	Date Considered	3/25/04
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement. This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Supplement to form 1449B/PTO

## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 20 of 24

### Complete if Known

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

178	SCHENK et al., "Therapeutic Approaches Related to Amyloid- $\beta$ Peptide and Alzheimer's Disease," <u>J. Med. Chem.</u> , 38(21):4141-4154 (1995).	—
312	SCHENK, et al., "Immunotherapy with beta-amyloid for Alzheimer's disease: a new frontier," <u>DNA Cell Biol.</u> , 20(11):679-81 (2001).	—
270	SCHENK, et al., " $\beta$ -peptide immunization," <u>Arch. Neurol.</u> , 57:934-936 (2000).	—
150	SELKOE, "Alzheimer's Disease: A Central Role for Amyloid," <u>J. Neuropathol. Exp. Neurol.</u> , 53(5): 438-447 (1994).	—
151	SELKOE, "Physiological production of the $\beta$ -amyloid protein and the mechanism of Alzheimer's disease," <u>Trends in Neurosciences</u> , 16(10): 403-409 (1993).	—
149	SELKOE, D.J., "Imaging Alzheimer's Amyloid," <u>Nat. Biotech.</u> , 18:823-824 (2000).	—
155	SELKOE, Dennis J., "Alzheimer's Disease: Genotypes, Phenotype, and Treatments," <u>Science</u> , 275:630-631 (1997).	—
152	SELKOE, Dennis J., "Amyloid Protein and Alzheimer's Disease.....," <u>Scientific American</u> , pgs. 68-78 (November, 1991).	—
153	SELKOE, Dennis J., "In the Beginning....," <u>Nature</u> , 354:432-433 (1991).	—
154	SELKOE, Dennis J., "The Molecular pathology of Alzheimer's Disease," <u>Neuron</u> , 6:487-498 (1991).	—
313	SELKOE, "The cell biology of beta-amyloid precursor protein and presenilin in Alzheimer's disease," <u>Trends Cell Biol.</u> , 8(11):447-53 (1998).	—
156	SEUBERT et al., "Isolation and quantification of soluble Alzheimer's $\beta$ -peptide from biological fluids," <u>Nature</u> , 359: 325-327 (1992).	—
157	SHIOSAKA, S., "Attempts to make models for Alzheimer's disease," <u>Neuroscience Res.</u> , 13:237-255 (1992).	—
330	SIGMUND, "Viewpoint: Are Studies in Genetically Altered Mice Out of Control," <u>Arterioscler Thromb Vasc Biol.</u> , 20:1425-1429 (2000).	—
396	SIGURDSSON et al., "Anti-priori antibodies for prophylaxis following prion exposure in mice," <u>Neurosciences Letters</u> , 336:185-187 (2003).	—

Examiner  
Signature


Date  
Considered

3/25/04

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitution for form 1449B/PTO		<b>Complete if Known</b>			
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,570		
		Filing Date	November 28, 2000		
		First Named Inventor	Schenk, Dale B.		
		Art Unit	1647		
		Examiner Name	Christopher Nichols		
Sheet	21	of	24	Attorney Docket Number	015270-005914US

384	SIGURDSSON et al., "Immunization Delays the Onset of Prion Disease in Mice," <u>American Journal of Pathology</u> , 161:13-17 (2002).	
314	SIGURDSSON, et al., "In vivo reversal of amyloid-beta lesions in rat brain," <u>J Neuropathol Exp Neurol.</u> , 59(1):11-17 (2000).	
400	SIGURDSSON et al., "A safer vaccine for Alzheimer's disease?," <u>Neurobiology of Aging</u> , 23:1001-1008 (2002).	
315	SINHA, et al., "Recent advances in the understanding of the processing of APP to beta amyloid peptide," <u>Ann N Y Acad Sci.</u> , 920:206-8 (2000).	
368	SIPE, "Amyloidosis," <u>Annu. Rev. Biochem.</u> , 61:947-975 (1992).	
337	SKOLNICK and FETROW, "From genes to protein structure and function: novel applications of computational approaches in the genomic era," <u>Trends in Biotech.</u> , 18(1):34-39 (2000).	
319	SMALL, et al. Alzheimer's disease and Abeta toxicity: from top to bottom. <u>Nat Rev Neurosci.</u> 2(8):595-8 (2001).	
158	SMITS et al., "Prion Protein and Scrapie Susceptibility," <u>Vet. Quart.</u> , 19(3): 101-105 (1997).	
185	SOLOMON and et al., "Modulation of The Catalytic Pathway of Carboxypeptidase A by Conjugation with Polyvinyl Alcohols," <u>Adv. Mol. Cell Biology</u> , 15A:33-45 (1996).	
<del>186</del>	<del>SOLOMON et al., "Activity of monoclonal antibodies in prevention of in vitro aggregation of their antigens," abstract from Department of Molecular Microbiology and Biotechnology, Tel Aviv University, Tel Aviv, Israel (publication date unknown)."</del>	
159	SOLOMON et al., "Disaggregation of Alzheimer $\beta$ -amyloid by site-directed mAb," <u>PNAS USA</u> , 94:4109-4112 (1997).	
160	SOLOMON et al., "Monoclonal antibodies inhibit in vitro fibrillar aggregation of the Alzheimer $\beta$ -amyloid peptide," <u>PNAS USA</u> , 93:452-455 (1996).	
<del>161</del>	<del>SOLOMON, A., "Pro-Rx (Protein Therapeutics)," University of Tennessee Medical Center (publication date unknown).</del>	
<del>162</del>	<del>SOLOMON, B., "New Approach Towards Fast Induction of Anti <math>\beta</math>-Amyloid Peptide Immune Response," Department of Molecular Microbiology &amp; Biotechnology, Tel Aviv University, Ramat Aviv, Tel Aviv, Israel (publication date unknown)."</del>	

Examiner Signature	<i>Ly Nichols</i>	Date Considered	3/25/04
--------------------	-------------------	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Submitting for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

22

of

24

**Complete if Known**

Application Number	09/724,570
Filing Date	November 28, 2000
First Named Inventor	Schenk, Dale B.
Art Unit	1647
Examiner Name	Christopher Nichols
Attorney Docket Number	015270-005914US

316	SOTO, et al. Beta sheet breaker peptides inhibit fibrillogenesis in a rat brain model of amyloidosis: implications for Alzheimer's therapy. <i>Nat Med.</i> 4(7):822-6 (1998).
179	SOUTHWICK et al., "Assessment of Amyloid $\beta$ protein in Cerebrospinal fluid as an Aid in the Diagnosis of Alzheimer's Disease," <i>J. Neurochemistry</i> , 66:259-265 (1996).
369	SPOONER et al., "The generation and characterization of potentially therapeutic A $\beta$ antibodies in mice: differences according to strain and immunization protocol," <i>Vaccine</i> , 21:290-297 (2002).
271	ST. GEORGE-HYSLOP et al., "Antibody clears senile plaques," <i>Nature</i> , 40:116-117 (1999).
338	STEIN et al., "Lack of Neurodegeneration in Transgenic Mice Overexpressing Mutant Amyloid Precursor Protein Is Associated with Increased Levels of Transthyretin and Activation of Cell Survival Pathways," <i>The Journal of Neuroscience</i> , 22(17):7380-7388 (September 1, 2002).
163	STOUTE et al., "A Preliminary Evaluation of a Recombinant Circumsporozoite Protein Vaccine Against <i>Plasmodium Falciparum Malaria</i> ", <i>N. Engl. J. Med.</i> , 336(2): 86-91 (1997).
164	STURCHLER-PIERRAT et al., "Two amyloid precursor protein transgenic mouse models with Alzheimer disease-like pathology," <i>PNAS</i> , 94: 13287-13292 (1997).
361	SU et al., "Intravascular infusions of soluble $\beta$ -amyloid compromise the blood-brain barrier, activate CNS Glial cells and induce peripheral hemorrhage," <i>Brain Research</i> , 818:105-107 (1999).
272	SZENDREI, et al., "The effects of aspartic acid-bond isomerization on in vitro properties of the amyloid $\beta$ -peptide as modeled with N-terminal decapeptide fragments," <i>Int. J. Peptide Protein Res.</i> , 47:289-296 (1996).
392	TAL et al., "Complete Freund's Adjuvant Immunization Prolongs Survival in Experimental Prion Disease in Mice," <i>Journal of Neuroscience Research</i> , 71:286-290 (2003).
399	TAN et al., "Amyloidosis," <i>Histopathology</i> , 25:403-414 (1994).
165	TANAKA et al., "NC-1900, an active fragment analog of arginine vasopressin, improves learning and memory deficits induced by beta-amyloid protein in rats," <i>European J. Pharmacology</i> , 352:135-142 (1998).
339	TENNENT et al., "Serum amyloid P component prevents proteolysis of the amyloid fibrils of Alzheimer's disease and systemic amyloidosis," <i>PNAS</i> , 92:4299-4303 (1995).
273	THORSETT, E.D. et al., "Therapeutic approaches to Alzheimer's disease," <i>Curr. Op. in Chem. Biology</i> , 4:377-382 (2000).

Examiner  
Signature

Date


Considered

3/25/04

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1




PTO/SB/08B (10-01)  
Approved for use through 10/31/2002. OMB 0851-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		<b>Complete If Known</b>	
		Application Number	09/724,570
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher Nichols
		Attorney Docket Number	015270-005914US

Sheet	23	of	24
-------	----	----	----

330	276	TJERNBERG et al., "Arrest of $\beta$ -amyloid fibril formation by a pentapeptide ligand," <u>Journal of Biological Chemistry</u> , 271:8545-8548 (1996).	—
	166	TRIEB et al., "Is Alzheimer beta amyloid precursor protein (APP) an autoantigen? Peptides corresponding to parts of the APP sequence stimulate T lymphocytes in normals, but not in patients with Alzheimer's disease," <u>Immunobiology</u> , 191(2-3):114-115 Abstract C.37, (1994).	—
	375	TSUZUKI et al., "Amyloid $\beta$ protein in rat soleus in choroquine-induced myopathy using end-specific antibodies for A $\beta$ 40 and A $\beta$ 42: immunohistochemical evidence for amyloid $\beta$ protein," <u>Neuroscience Letters</u> , 2002:77-80 (1995).	—
	167	VAN GOOL et al., "Concentrations of amyloid- $\beta$ protein in cerebrospinal fluid increase with age in patients free from neurodegenerative disease," <u>Neuroscience Letters</u> , 172:122-124 (1994).	—
	317	VEHMAS, et al. beta-Amyloid peptide vaccination results in marked changes in serum and brain A $\beta$ levels in APPswe/PS1 DeltaE9 mice, as detected by SELDI-TOF-based ProteinChip® technology. <u>ONA Cell Biol.</u> (11):713 21 (2001).	—
	168	VERBEEK et al., "Accumulation of Intercellular Adhesion Molecule-1 in Senile Plaques in Brain Tissue of patients with Alzheimer's Disease," <u>Amer. Journ. Pathology</u> , 144(1):104-116 (1994).	—
	410	VERMA et al., "Gene therapy - promises, problems and prospects," <u>Nature</u> , 389:239-242 (1997).	—
	169	WALKER et al., "Labeling of Cerebral Amyloid <i>In Vivo</i> with a Monoclonal Antibody," <u>J. Neuropath. Exp. Neurology</u> , 53(4):377-383 (1994).	—
	274	WEINER et al., "Nasal administration of amyloid- $\beta$ peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease," <u>Annals of Neurology</u> , 48:567-579 (2000).	—
	171	WEINER et al., "ORAL TOLERANCE: Immunologic Mechanisms and Treatment of Animal and Human Organ-Specific Autoimmune Diseases by Oral Administration of Autoantigens," <u>Annu. Rev. Immunol.</u> , 12:809-837 (1994).	—
	172	WEISSMANN et al., "Bovine spongiform encephalopathy and early onset variant Creutzfeldt-Jakob disease," <u>Curr. Opin. Neurobiol.</u> , 7: 695-700 (1997).	—
✓	387	WELDON et al., "Neurotoxicity of A $\beta$ Peptide: Confocal Imaging of Cellular Changes Induced by - Amyloid in Rat CNS <i>In Vivo</i> ," <u>Society for Neuroscience Abstracts</u> , 22(Part 1) (1996). ****	—
330	180	WEN, G.Y., "Alzheimer's Disease and Risk Factors," <u>J. Food Drug Analysis</u> , 6(2):465-476 (1998).	—

Examiner Signature		Date Considered	3/25/01
--------------------	---	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1





→

PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1448B/PTO		<b>Complete If Known</b>	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (use as many sheets as necessary)		Application Number	09/724,570
		Filing Date	November 28, 2000
		First Named Inventor	Schenk, Dale B.
		Art Unit	1647
		Examiner Name	Christopher Nichols
		Attorney Docket Number	015270-005914US
Sheet	24	of	24

170	WENGENACK et al., "Targeting Alzheimer amyloid plaques in vivo," <u>Nature Biotech.</u> , 18:868-872 (2000).
<del>223</del>	<del>WISCONSIN ALUMNI RESEARCH FOUNDATION, "Injection of Newborn Mice with Seven Chemical Adjuvants to Help Determine Their Safety in Use in Biologicals", U.S. Govt. Res. Develop. Rep., 70(24), 56. (Publication date unknown.)</del>
385	WISNIEWSKI et al., "Therapeutics in Alzheimer's and Prion Diseases," <u>Biochemical Society Transactions</u> , 30(4):-574-587 (2002).
219	WONG et al., "Neuritic Plaques and Cerebrovascular Amyloid in Alzheimer Disease are Antigenically Related," <u>PNAS USA</u> , 82:8729-8732 (1985).
173	WOOD et al., "Amyloid precursor protein processing and A $\beta$ 42 deposition in a transgenic mouse model of Alzheimer disease," <u>PNAS USA</u> , 94: 1550-1555 (1997).
275	WU, et al., "Drug targeting of a peptide radiopharmaceutical through the primate blood-brain barrier in vivo with a monoclonal antibody to the human insulin receptor," <u>J. Clin. Invest.</u> , 100:1804-1812 (1997).
292	YAMAGUCHI et al., Diffuse plaques associated with astroglial amyloid $\beta$ protein, possibly showing a disappearing stage of senile plaques," <u>Acta Neuropathol.</u> , 95:217-222 (1998).
290	YOUNKIN, "Amyloid $\beta$ vaccination: reduced plaques and improved cognition," <u>Nature Medicine</u> , 7:18-19 (2001).

Examiner Signature		Date Considered	3/25/04
--------------------	--	-----------------	---------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.  
60106599 v1